Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.37), versus ($5.94) reported last year.

Voyager reported cash, cash equivalents and marketable securities of $204.0 million as of June 30, 2016. Voyager continues to expect to end 2016 with cash, cash equivalents and marketable securities of $160.0 million and that its existing cash, cash equivalents and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into 2019.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.